Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bleomycin
Drug ID BADD_D00280
Description A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
Indications and Usage For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.
Marketing Status Prescription; Discontinued
ATC Code L01DC01
DrugBank ID DB00290
KEGG ID D07535
MeSH ID D001761
PubChem ID 5460769
TTD Drug ID D06UVD
NDC Product Code 61703-323; 0143-9240; 0703-3155; 16714-908; 0409-0332; 61703-332; 16714-886; 0143-9241; 70121-1567; 0703-3154; 0409-0323; 69097-364
Synonyms Bleomycin | Bleomycins | BLEO-cell | BLEO cell | BLEOcell | Bleolem | Bléomycine Bellon | Bellon, Bléomycine | Bleomycin A2 | Bleomycin A(2) | Bleomycin B2 | Bleomycin B(2) | Bleomycin Sulfate | Sulfate, Bleomycin | Bleomycinum Mack | Mack, Bleomycinum | Blenoxane | Blanoxan | Bleomicina
Chemical Information
Molecular Formula C55H84N17O21S3+
CAS Registry Number 11056-06-7
SMILES CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O) OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6 =NC(=CS6)C(=O)NCCC[S+](C)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cystitis20.03.02.002; 11.01.14.001--
Cystitis haemorrhagic20.03.02.003--Not Available
Deafness04.02.01.0010.002131%Not Available
Death08.04.01.001--
Dermatitis23.03.04.002--Not Available
Diarrhoea07.02.01.001--
Dilatation ventricular02.04.02.0260.000799%Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.015--Not Available
Dyspnoea22.02.01.004; 02.01.03.002--
Ecchymosis24.07.06.002; 23.06.01.001; 01.01.03.0010.000533%Not Available
Erythema23.03.06.001--Not Available
Extravasation08.01.03.008--Not Available
Fatigue08.01.01.002--
Febrile neutropenia08.05.02.004; 01.02.03.0020.004263%
Feeling abnormal08.01.09.014--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Haematuria24.07.01.047; 20.02.01.006--
Haemoglobin13.01.05.018--Not Available
Haemolytic uraemic syndrome20.01.03.011; 01.06.02.0010.000533%
Hyperaesthesia17.02.06.004--Not Available
Hyperkeratosis23.01.01.001--
Hypersensitivity10.01.03.003--
Hypertension24.08.02.001--
Hypoaesthesia17.02.06.023--Not Available
Hypomagnesaemia14.04.02.001--
Hypotension24.06.03.0020.000799%
Hypoxia22.02.02.0030.000533%
Ichthyosis23.01.02.002; 03.05.01.004--Not Available
Ichthyosis acquired23.01.02.001--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages